Intech Investment Management LLC Buys Shares of 18,014 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 18,014 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

Other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter valued at $61,000. Bank of New York Mellon Corp grew its position in shares of Vanda Pharmaceuticals by 8.7% during the second quarter. Bank of New York Mellon Corp now owns 257,995 shares of the biopharmaceutical company’s stock worth $1,458,000 after acquiring an additional 20,721 shares during the last quarter. Panagora Asset Management Inc. grew its position in shares of Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,509 shares during the last quarter. Finally, Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $1,090,000. Institutional investors own 88.14% of the company’s stock.

Insiders Place Their Bets

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several recent analyst reports. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a “buy” rating and a $18.00 target price for the company. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Tuesday, December 3rd. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Up 1.3 %

VNDA stock opened at $4.84 on Monday. The company has a 50-day simple moving average of $4.84 and a 200 day simple moving average of $5.25. The company has a market capitalization of $282.22 million, a P/E ratio of -17.29 and a beta of 0.76. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.75.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.